Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.44 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22648361 | 0.84 | KLF10 (0.48) | CYP2C19EPHX2NR1H4KLF10CYP1A2 | |
| SCHEMBL10235441 | 0.82 | CYP2C19 (0.47) | CYP2C19EPHX2NR1H4CYP1A2ALDH1A1 | |
| SCHEMBL22275799 | 0.81 | KLF10 (0.53) | CYP2C19EPHX2KLF10CYP1A2ALDH1A1 | |
| SCHEMBL4517620 | 0.80 | CYP2C19 (0.43) | CYP2C19EPHX2NR1H4CYP1A2ALDH1A1 | |
| SCHEMBL25530524 | 0.80 | EPHX2 (0.43) | CYP2C19EPHX2NR1H4CYP1A2ALDH1A1 | |
| SCHEMBL92913 | 0.80 | PDE2A (0.49) | ALDH1A1GAAKDM4EMAPTSLC6A4 | |
| SCHEMBL30523915 | 0.80 | PDE2A (0.49) | ALDH1A1GAAKDM4EMAPTSLC6A4 | |
| SCHEMBL12401848 | 0.80 | PNMT (0.43) | CYP2C19EPHX2NR1H4CYP1A2ALDH1A1 | |
| SCHEMBL1447610 | 0.79 | KLF10 (0.47) | CYP2C19EPHX2KLF10CYP1A2ALDH1A1 | |
| SCHEMBL7979494 | 0.79 | KLF10 (0.47) | CYP2C19EPHX2NR1H4KLF10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-7632830-B2 | Lactam compounds and pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2009-12-15 | — | — | US | disclosed |
| EP-1346993-B1 | LACTAM COMPOUNDS AND MEDICAL USE THEREOF | AJINOMOTO KK (JP) | 2009-10-21 | — | — | EP | disclosed |
| US-20080096862-A1 | LACTAM COMPOUNDS AND PHARMACEUTICAL USE THEREOF | AJINOMOTO CO., INC. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-7326701-B2 | Lactam compounds and pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2008-02-05 | — | — | US | disclosed |
| US-7153850-B2 | Lactam compounds and pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060189597-A1 | Lactam compounds and pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20040048847-A1 | Lactam compounds and pharmaceutical use thereof | AJINOMOTO CO. INC (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1346993-A1 | LACTAM COMPOUNDS AND MEDICINAL USE THEREOF | Ajinomoto Co., Inc. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189597-A1 | Lactam compounds and pharmaceutical use thereof | SLC2A4, SLC2A8, SLC2A1 | CYP2C19 2211/4885EPHX2 4637/4885NR1H4 3094/4885 |
| US-20040048847-A1 | Lactam compounds and pharmaceutical use thereof | SLC2A4, SLC2A8, SLC2A1 | CYP2C19 2211/4885EPHX2 4637/4885NR1H4 3094/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP2C19 465/4885EPHX2 1575/4885NR1H4 258/4885 |
| US-20080096862-A1 | LACTAM COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SLC2A4, SLC2A8, SLC2A1 | CYP2C19 2211/4885EPHX2 4637/4885NR1H4 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.